Immunogenicity Assessment Advisor
Assess immunogenicity risk, design ADA detection strategies, and generate regulatory reports
What You Can Do
You can conduct molecule-specific immunogenicity risk stratification, design ADA detection strategies with assay platform selection and bridging validation, and interpret complex immunogenicity data for clinical and regulatory communication. The skill guides you through ICH S6, FDA 2014 guidance, and EMA CHMP expectations to translate ADA prevalence, titer, and neutralizing capacity into actionable clinical risk assessments and submission-ready reports.
Features
evaluate immunogenicity hazard by molecule class (protein, mAb, conjugate, ADC), manufacturing process, and patient population before study initiation
select screening and confirmatory platforms, establish bridging approaches, and define sensitivity requirements aligned with clinical needs
contextualize prevalence, titer kinetics, and neutralizing antibody capacity within clinical safety signals and PK/PD relationships
structure immunogenicity sections for clinical overviews, safety updates, and integrated summaries compliant with FDA/EMA submission standards
apply bioanalytical method validation principles specific to ADA detection (specificity, sensitivity, cut points, incubation conditions)
recommend sampling frequency, time points, and patient subgroup analysis strategies for immunogenicity monitoring
assess immunogenicity profile differences between manufacturing changes, formulations, or clinical populations
Example Output
Example 1: Risk Assessment Output
Molecule: Recombinant human IL-2 fusion protein
Immunogenicity Risk Level: MODERATE-HIGH
Key Risk Factors:
- Novel fusion architecture (increased immunogenicity vs. native IL-2)
- Subcutaneous administration (higher ADA risk than IV)
- Chronic dosing (repeated exposure)
Recommended Strategy:
- Sensitive bridging ELISA + confirmatory assay (neutralization)
- Sampling: baseline, weeks 2, 4, 8, 12, EOT, follow-up
- Pre-dose and post-dose sampling recommended
- Patient subgroup analysis: prior IL-2 exposure vs. naïve
Example 2: ADA Detection Strategy Output
Recommended Two-Tier Assay:
- Screening: Electrochemiluminescence (ECL) platform — high sensitivity for low-titer ADA
- Confirmation: Surface plasmon resonance (SPR) — specificity and kinetic data
Assay Characteristics:
- Screening cut point: 0.15 μg/mL (based on 1.645 × SD of negative control)
- Confirmatory cut point: 0.08 μg/mL
- Expected sensitivity: 98% at 0.5 μg/mL equivalence
- Bridging validation: correlation R² > 0.95 with legacy ELISA
Example 3: Regulatory Reporting
ADA Prevalence Summary:
- Overall: 12/89 subjects (13.5%) developed treatment-emergent ADA
- Median titer: 3.2 μg/mL (range: 0.08–18.4)
- Neutralizing capacity: 8/12 ADA+ subjects (67%) showed in vitro neutralization
- Clinical impact: No dose adjustment or discontinuation due to ADA alone; no correlation with PK loss of response
What's Included
- SKILL.md: complete instruction file with risk stratification framework, assay selection logic, and regulatory guidance context
- Immunogenicity Risk Assessment Template: molecule-class-specific checklist for hazard evaluation and strategy recommendation
- ADA Assay Strategy Worksheet: platform selection matrix, bridging validation checklist, and cut-point justification framework
- Data Interpretation Guide: prevalence categorization, titer kinetics interpretation, and clinical correlation decision tree
- Regulatory Submission Checklist: FDA/EMA section-by-section requirements for clinical overview, safety update, and integrated immunogenicity summary
Who It's For
- Bioanalytical scientists — designing ADA detection strategies and validating immunogenicity assays in discovery/development
- Clinical development scientists — interpreting immunogenicity data, assessing clinical risk, and recommending dose/monitoring adjustments
- Regulatory affairs specialists — preparing immunogenicity sections of CTD modules, clinical overviews, and safety updates for FDA/EMA submissions
- Program managers — evaluating immunogenicity risk at program inception and accelerating timelines through upfront strategy clarity
- Quality/CMC scientists — understanding manufacturing changes' immunogenicity impact and supporting comparability studies
Best For
- Immunogenicity risk assessment for new biopharmaceutical programs (proteins, mAbs, conjugates, ADCs)
- ADA assay platform selection and bridging strategy design
- Clinical immunogenicity study report preparation and data interpretation
- Regulatory submission drafting (clinical overview, integrated safety summary, specific immunogenicity sections)
- Post-approval immunogenicity signal investigation and manufacturing change impact assessment
- Cross-functional immunogenicity alignment meetings with clinical, regulatory, and CMC teams
You might also like
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-wThis skill interprets your FEA simulation results and extracts actionable design improvements. You can pinpoint stress concentrations, validate designs against safety factors and material limits, and receive specific geometry recommendations to reduce weight or improve performance. By automating FEA post-processing, you compress design iteration cycles and make engineering decisions faster.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w
You can analyze equipment sensors, operational logs, and historical maintenance data to predict failures weeks in advance. Claude generates actionable maintenance schedules, identifies high-risk assets, and calculates the financial impact of preventive vs. reactive maintenance. This skill transforms raw operational data into strategic maintenance decisions that minimize downtime and extend asset life.
by kody-w